BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Авг. 18, 2022
Heterologous
prime/boost
vaccination
with
a
vector-based
approach
(ChAdOx-1nCov-19,
ChAd)
followed
by
an
mRNA
vaccine
(e.g.
BNT162b2,
BNT)
has
been
reported
to
be
superior
in
inducing
protective
immunity
compared
repeated
application
of
the
same
vaccine.
However,
data
comparing
decline
after
homologous
and
heterologous
as
well
effects
third
ChAd/BNT
are
lacking.
Here
we
show
longitudinal
monitoring
ChAd/ChAd
(n
=
41)
88)
vaccinated
individuals
impact
BNT.
The
greatly
augments
waning
anti-spike
IgG
but
results
only
moderate
increase
spike-specific
CD4
+
CD8
T
cell
numbers
both
groups,
frequencies
already
present
second
group.
More
importantly,
efficiently
restores
neutralizing
antibody
responses
against
Alpha,
Beta,
Gamma,
Delta
variants
virus,
activity
B.1.1.529
(Omicron)
variant
remains
severely
impaired.
In
summary,
inferior
SARS-CoV-2
specific
immune
following
can
compensated
BNT
vaccination,
which
might
influence
choice
type
for
subsequent
boosts.
Язык: Английский
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
Human Vaccines & Immunotherapeutics,
Год журнала:
2023,
Номер
19(1)
Опубликована: Янв. 2, 2023
Introduction
of
primary
COVID-19
vaccination
has
helped
reduce
severe
disease
and
death
caused
by
SARS-CoV-2
infection.
Understanding
the
protection
conferred
heterologous
booster
regimens
informs
alternative
strategies
that
enable
programmatic
resilience
can
catalyze
vaccine
confidence
coverage.
Inactivated
vaccines
are
among
most
widely
used
worldwide.
This
review
synthesizes
available
evidence
identified
as
May
26,
2022,
on
safety,
immunogenicity,
effectiveness
a
BNT162b2
(Pfizer-BioNTech)
mRNA
dose
after
an
inactivated
series,
to
help
protect
against
COVID-19.
Evidence
showed
BNT16b2
enhances
immunogenicity
improves
COVID-19,
no
new
safety
concerns
were
with
series
combinations.
Язык: Английский
Enhanced Production of Lipid Mediators in Plasma and Activation of DNA Damage Pathways in PBMCs Are Correlated With the Severity of Ancestral SARS‐CoV‐2 Infection
The FASEB Journal,
Год журнала:
2025,
Номер
39(9)
Опубликована: Май 5, 2025
ABSTRACT
Many
questions
remain
unanswered
regarding
the
implication
of
genetics
and
lipid
metabolites
with
severe
SARS‐CoV‐2
infections.
We
performed
bulk
RNA‐seq
a
total
fatty
acid
panel
analysis
on
PBMCs
plasma
collected
from
10
infected
uninfected
patients.
Univariate
comparison
using
Mann–Whitney
U
‐test
revealed
that
six
were
significantly
increased
in
COVID‐19
patients,
including
mediators
arachidonic
(AA)
eicosapentaenoic
(EPA),
which
both
give
rise
to
eicosanoids.
Key
lipids
implicated
inflammation,
AA
EPA,
along
acids
DHA
DPA,
positively
correlated
WHO
disease
severity
score.
Analysis
our
dataset
demonstrated
distinct
transcriptional
profiles
leading
segregation
patients
based
Ontology,
KEGG,
Reactome
identified
several
key
pathways
nodes
enriched
for
genes
related
innate
immunity,
interactions
between
lymphoid
nonlymphoid
cells,
interleukin
signaling,
subsequent
DNA
damage
pathways.
EPA
levels
heightened
cell
cycling
observed
high
studied
gene
expression
nasopharyngeal
swabs
58
healthy
participants
eicosanoid
synthesis,
such
as
alox5,
alox12,
alox15B,
specifically
up‐regulated
score
types
nasopharynx,
especially
goblet
cells
across
different
viral
variants
(Deta
Omicron).
Using
published
nasal
scRNA‐seq
datasets
we
evaluated
ALOX5
,
ALOX15,
ALOX15B
groups.
Altogether,
study
highlights
fact
increase
specific
inflammation
required
their
synthesis
infection.
Язык: Английский
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
Open Forum Infectious Diseases,
Год журнала:
2022,
Номер
9(8)
Опубликована: Авг. 1, 2022
Ongoing
outbreaks
of
coronavirus
disease
2019
(COVID-19)
are
driven
by
waning
immunity
following
primary
immunizations
and
emergence
new
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
variants
that
escape
vaccine-induced
neutralizing
antibodies.
It
has
been
suggested
heterologous
boosters
could
enhance
potentially
maintain
population
immunity.
We
assessed
the
immunogenicity
reactogenicity
booster
doses
different
formulations
aluminium
hydroxide-adjuvanted
SCB-2019
vaccine
(9
μg
SCB-2019,
with
or
without
CpG-1018
adjuvant,
30
CpG-1018)
in
Brazilian
adults
primed
ChAdOx1-S
vector
vaccine.
S-protein
antibodies
ACE2-binding
inhibition
were
measured
enzyme-linked
immunosorbent
assay
(ELISA)
on
days
1,
15,
29.
Participants
self-reported
solicited
adverse
events
reactions.
All
increased
ELISA
ACE2
binding
to
a
greater
extent
than
ChAdOx1-S.
After
+
CpG
hydroxide,
titers
against
wild-type
significantly
higher
after
15
29,
as
strain
Beta,
Gamma,
Delta,
Omicron
variants.
Boosting
was
well
tolerated,
no
vaccine-related
serious
events.
ChAdOx1-S-primed
induced
levels
SARS-CoV-2
homologous
booster,
highest
responses
being
30-μg
hydroxide
formulation.
NCT05087368.
Язык: Английский
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2022,
Номер
unknown
Опубликована: Июль 28, 2022
Abstract
Background
Heterologous
orally
administered
adenovirus
type-5
vector-based
COVID-19
vaccine
(Ad5-nCoV)
in
individuals
who
were
primed
with
two-dose
CoronaVac
(an
inactivated
SARS-CoV-2
vaccine,
by
Sinovac)
previously,
has
been
reported
to
be
safe
and
highly
immunogenic
within
28
days
post-boosting.
However,
antibody
persistence
safety
up
6
months
of
this
regimen
are
not
yet.
Methods
This
is
a
randomized,
open
label,
single-center
trial
on
immunogenicity
heterologous
boost
immunization
an
aerosolised
Ad5-nCoV
vs.
homologous
after
priming
Chinese
adults
aged
18
years
older
(
NCT05043259
).
We
followed
the
participants
trial,
including
140
low-dose
group,
139
high-dose
group
for
months.
Neutralising
antibodies
(NAbs)
against
live
wild-type
virus
omicron
variant,
receptor-binding
domain
(RBD)-specific
IgG
detected
serum
samples
collected
at
days,
3
months,
booster
dose.
Serious
adverse
events
(SAEs)
documented
till
month
6.
Results
The
immunisation
groups
had
NAb
GMTs
1937.3
[95%
CI
1466.9,
2558.4]
1350.8
952.6,
1915.3],
which
26.4
folds
18.4
higher
than
that
did
(73.5
52.3,
103.3])
days.
530.1
(95%
412.5,
681.1)
457.6
(95%CI
349.4,
599.2),
26.0
22.4
(20.4
[95%CI
14.3,
29.1])
respectively.
At
312.9
237.7,
411.8)
251.1
178.2,
354.0),
30.1
24.1
(10.4
7.8,
14.0]),
Additionally,
variant
52.0
37.2,
72.6)
23.1
15.7,
33.9)
27.9
18.8,
41.3)
23.3
16.2,
33.3)
16.0
10.9,
23.5)
12.0
8.5,
16.8)
nearly
all
no
detectable
NAbs
either
or
No
vaccine-related
SAEs
observed.
Conclusions
These
data
suggested
following
was
persistently
more
three-dose
CoronaVac,
although
immune
responses
waned
over
time.
Язык: Английский
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
Frontiers in Immunology,
Год журнала:
2022,
Номер
13
Опубликована: Дек. 21, 2022
With
the
emergence
of
novel
Severe
Acute
Respiratory
Syndrome
Coronavirus-2
(SARS-CoV-2)
Variants
Concern
(VOCs),
vaccination
studies
that
elucidate
efficiency
and
effectiveness
a
campaign
are
critical
to
assess
durability
protective
immunity
provided
by
vaccines.
SARS-CoV-2
vaccines
have
been
found
induce
robust
humoral
cell-mediated
in
individuals
vaccinated
with
homologous
regimens.
Recent
also
suggest
improved
immune
response
against
when
heterologous
strategies
employed.
Yet,
few
data
exist
on
extent
which
prime-boost-boost
vaccinations
two
different
vaccine
platforms
an
impact
T
responses
special
emphasis
currently
dominantly
circulating
Omicron
strain.
In
this
study,
we
collected
serum
peripheral
blood
mononuclear
cells
(PBMCs)
from
57
study
participants
median
35-year
old’s
working
health
care
field,
who
received
Neutralization
assays
revealed
but
decreased
neutralization
VOC,
including
BA.1
BA.4/5,
compared
WT
all
groups
increased
binding
neutralizing
antibodies
titers
mRNA
participants.
By
investigating
cytokine
production,
prime-boost-boost-vaccination
induces
CD4
+
CD8
cells.
Collectively,
our
results
indicate
cell
mediated
participants,
might
serve
as
guide
for
policy
decisions.
Язык: Английский
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Vaccine,
Год журнала:
2024,
Номер
42(7), С. 1665 - 1672
Опубликована: Фев. 10, 2024
Язык: Английский
Humoral Immune Response to CoronaVac in Turkish Adults
Vaccines,
Год журнала:
2023,
Номер
11(2), С. 216 - 216
Опубликована: Янв. 18, 2023
While
most
approved
vaccines
are
based
on
the
viral
spike
protein
or
its
immunogenic
regions,
inactivated
whole-virion
(e.g.,
CoronaVac)
contain
additional
antigens
that
may
enhance
protection.
This
study
analyzes
short-term
humoral
responses
against
SARS-CoV-2
(S1)
and
nucleocapsid
(NCP)
in
50
Turkish
adults
without
previous
infection
after
CoronaVac
immunization.
Samples
were
collected
before
vaccination
(t0),
28–29
days
first
vaccine
dose
prior
to
second
(t1),
as
well
14–15
(t2).
Anti-S1
IgG
IgA
anti-NCP
quantified
using
ELISA.
At
t1,
seroconversion
rates
for
anti-S1
IgG,
30.0%,
28.0%
4.0%,
respectively,
increasing
significantly
98.0%,
78.0%
40.0%
at
t2.
The
median
(t2)
was
below
positivity
cut-off,
while
medians
positive.
levels
strongly
correlated
with
(rs
=
0.767,
p
<
0.001)
0.683,
0.001).
In
conclusion,
two
doses
induced
significant
increases
antibodies
S1
NCP.
Despite
strong
correlations
between
antibody
concentrations,
of
S1-specific
exceed
those
NCP-specific
early
weeks
dose.
Язык: Английский
Cellular and Humoral Immune Responses to Vaccination for COVID-19 Are Negatively Impacted by Senescent T Cells: A Case Report
Vaccines,
Год журнала:
2023,
Номер
11(4), С. 840 - 840
Опубликована: Апрель 14, 2023
Herein,
we
aimed
to
follow
up
on
the
cellular
and
humoral
immune
responses
of
a
group
individuals
who
initially
received
CoronaVac
vaccine,
followed
by
booster
with
Pfizer
vaccine.Blood
samples
were
collected:
before
30
days
after
first
dose;
30,
90,
180
second
dose,
also
20
vaccine.Whilst
positivity
gamma
interferon-type
response
increased
neutralizing
IgG
antibody
levels
only
raised
drop
in
these
90
days.
The
vaccine
elicited
robust
response.
A
higher
number
double-negative
senescent
T
cells,
as
well
pro-inflammatory
cytokines
found
participants
lower
responses.CoronaVac
an
early
response,
which
dropped
dose.
significantly
enhanced
responses.
Furthermore,
systemic
status
was
volunteers
presented
could
putatively
impair
vaccination.
Язык: Английский
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2022,
Номер
unknown
Опубликована: Июнь 2, 2022
ABSTRACT
Background
Ongoing
outbreaks
of
COVID-19
are
driven
by
waning
immunity
following
primary
immunizations
and
emergence
new
SARS-CoV-2
variants
which
escape
vaccine-induced
neutralizing
antibodies.
It
has
been
suggested
that
heterologous
boosters
could
enhance
potentially
maintain
population
immunity.
Methods
We
assessed
immunogenicity
reactogenicity
booster
doses
different
formulations
alum-adjuvanted
SCB-2019
vaccine
(9
μg
with
or
without
CpG-1018
adjuvant,
30
CpG-1018)
in
Brazilian
adults
primed
ChAdOx1-S
vector
vaccine.
S-protein
antibodies
ACE2-binding
inhibition
were
measured
ELISA
on
Days
1,
15
29.
Participants
self-reported
solicited
adverse
events
reactions.
Results
All
increased
ACE2
binding
to
a
greater
extent
than
ChAdOx1-S.
After
SCB-2019+CpG+alum
titers
against
wild-type
significantly
higher
after
29,
as
strain
Beta,
Gamma,
Delta,
Omicron
variants.
Boosting
was
well
tolerated
no
vaccine-related
serious
severe
events.
Conclusions
ChAdOx1-S-primed
induced
levels
homologous
booster,
highest
responses
being
the
formulation.
Язык: Английский